Carter HB - Search Results

1

Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.

Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Carter HB, et al. JAMA. 1997 May 14;277(18):1456-60. JAMA. 1997. PMID: 9145718

2

Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging.

Wright EJ, Fang J, Metter EJ, Partin AW, Landis P, Chan D, Carter H. Wright EJ, et al. J Urol. 2002 Jun;167(6):2484-7; discussion 2487-8. doi: 10.1016/s0022-5347(05)65010-0. J Urol. 2002. PMID: 11992063

3

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging.

Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Fang J, et al. Among authors: carter hb. Urology. 2001 Sep;58(3):411-6. doi: 10.1016/s0090-4295(01)01304-8. Urology. 2001. PMID: 11549490

4

Nonpalpable prostate cancer detected in the prostate-specific antigen era.

Carter HB. Carter HB. World J Urol. 1997;15(6):329-30. doi: 10.1007/BF01300178. World J Urol. 1997. PMID: 9436280 No abstract available.

5

Treatment of prostate cancer--a controversial issue.

Carter HB. Carter HB. J Urol. 1997 Oct;158(4):1476. doi: 10.1016/s0022-5347(01)64246-0. J Urol. 1997. PMID: 9302146 No abstract available.

6

Multicenter comparison of the diagnostic performance of free prostate-specific antigen.

Thiel RP, Oesterling JE, Wojno KJ, Partin AW, Chan DW, Carter HB, Stamey TA, Prestigiacomo AR, Brawer MK, Petteway JC, Carlson G, Luderer AA. Thiel RP, et al. Among authors: carter hb. Urology. 1996 Dec;48(6A Suppl):45-50. doi: 10.1016/s0090-4295(96)00609-7. Urology. 1996. PMID: 8973699 Clinical Trial.

7

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.

Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Partin AW, et al. Among authors: carter hb. Urology. 1994 May;43(5):649-59. doi: 10.1016/0090-4295(94)90180-5. Urology. 1994. PMID: 7513108

8

Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.

Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB; Baltimore Longitudinal Study on Aging. Harman SM, et al. Among authors: carter hb. J Clin Endocrinol Metab. 2000 Nov;85(11):4258-65. doi: 10.1210/jcem.85.11.6990. J Clin Endocrinol Metab. 2000. PMID: 11095464

9

Mixed-effects regression models for studying the natural history of prostate disease.

Pearson JD, Morrell CH, Landis PK, Carter HB, Brant LJ. Pearson JD, et al. Among authors: carter hb. Stat Med. 1994 Mar 15-Apr 15;13(5-7):587-601. doi: 10.1002/sim.4780130520. Stat Med. 1994. PMID: 7517570

10

Prostate cancer diagnosis.

Carter HB. Carter HB. J Urol. 1994 Oct;152(4):1168-9. doi: 10.1016/s0022-5347(17)32529-6. J Urol. 1994. PMID: 7520950 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results